Mass vaccination campaigns with PsA-tetanus toxoid (PsA-TT; MenAfriVac) began in 2010 in Burkina Faso, Mali, and Niger and continue to date, with 6 countries having the entire populace 1-29 years of age vaccinated and 9 more having partially vaccinated their target population [5] . Ongoing surveillance shows that no cases of MenA disease have occurred in vaccinated individuals [5] , but the longevity of this protective immune response is not known, and the immunologic marker for persistence of protection is not known. Historically, clinical efficacy of PsA vaccines was correlated with anti-PsA antibody concentrations of ≥2 µg/mL [6] . Alternatively, because antibody-dependent, complement-mediated bactericidal killing is the primary protective mechanism against invasive meningococcal disease [7, 8] , serum bactericidal activity (SBA) assays have been used as surrogates of protection [9] .
SBA assays use heat-inactivated test sera and either human or baby rabbit complement as an exogenous complement source (hSBA or rSBA, respectively). The rSBA assay was used to support licensure of group C conjugate vaccines in Europe [10] , and for the registration and prequalification of PsA-TT [11, 12] . However, N. meningitidis is more sensitive to killing in rabbit vs human complement, due in part to the ability of N. meningitidis to diminish complement-mediated killing by binding regulatory proteins such as factor H from human but not rabbit serum [13] . Although both assays are still being used to assess meningococcal vaccines [6] , correlation between titers measured by rSBA and hSBA, especially in infants and children, has not been shown [14, 15] .
In this study, we measured the immune response to PsA-TT in African study subjects aged 2-29 years using a pooled hSBA assay [16] . The data presented extend the previously published study that compared the immunogenicity of the PsA-TT vaccine to a quadrivalent polysaccharide vaccine (PsACWY) in 900 African subjects aged 2-29 years [17] using rSBA assays and antipolysaccharide immunoglobulin G (IgG) enzymelinked immunosorbent assays (ELISAs).
METHODS

Study Population
For this analysis, 360 individuals stratified among the age groups 2-5, 6-10, 11-17, and 18-29 years were randomly selected from an MVP safety and immunogenicity study conducted in Mali, The Gambia, and Senegal [17] . In the original study, individuals were randomized 2:1 to receive either the PsA-TT or the PsAC-WY vaccine. Sera obtained at study weeks 0, 4, and 52 for these subjects were tested in hSBAs blinded to vaccine group.
Testing Laboratories
The immunogenicity of the vaccine was determined by rSBA (Public Health England, Manchester, UK) [17] , group A-specific IgG ELISA (Centers for Disease Control and Prevention [CDC], Atlanta, Georgia) [17] , and hSBA (Center for Biologics Evaluation and Research, Bethesda, Maryland) [16] .
Serum Bactericidal Assays
SBA assays were performed against the group A target strain, CDC F8238 ( phenotype A:4,21:P1.20,9,L11), as previously described [18] . The complement source used in rSBA assays was active serum from 3-to 4-week-old rabbits (Pel Freez Biologicals). The complement source used in hSBA assays was pooled active sera that met screening criteria obtained from healthy adult blood donors [16] . For both rSBA and hSBA, titers were expressed as the reciprocal of the highest serum dilutions yielding ≥50% killing after 60 minutes for rSBA and 90 minutes for hSBA. The hSBA and rSBA titers below the lower limit of quantitation (LLOQ = 4) were assigned a value of 2 when calculating geometric means and 4 when calculating 4-fold response.
Group A-Specific IgG
Group A-specific IgG levels were determined using an ELISA as described by Carlone et al [19] , except that the reference serum CDC 1992 and monoclonal antihuman IgG Fc labeled with horseradish peroxidase (Hybridoma Reagent Laboratory, Baltimore, Maryland) were used [20] . IgG ELISA concentrations below the LLOQ (<0.2 µg/mL) were assigned values of 0.1 µg/mL and 0.2 µg/mL when calculating geometric means and ≥4-fold response, respectively.
Data Analysis
Results of SBA assays and the group A-specific IgG ELISA from each time point were log-transformed prior to analysis. Geometric means were calculated with 95% confidence intervals (CIs). Fold rise was calculated by comparing titers or concentrations at a given time point to the prevaccination titers or concentrations at week 0. The proportion of subjects with assay results showing a ≥4-fold rise and results at or above selected thresholds were calculated. Significant differences in proportions between vaccine groups were calculated using Fisher exact test. Geometric means and differences in geometric means between vaccination groups at specific time points and between time points within a given study group were derived using an analysis of variance model taking into account the repeated-measures nature of the design. Pearson correlation coefficients were calculated to study the relationship between the different immunologic assays. The κ statistic was used to measure the agreement between the thresholds of the different assays.
RESULTS
Study Population
For this analysis, 360 of the original 900 individuals were randomly selected within the age-stratified groups 2-5, 6-10, 11-17, and 18-29 years, maintaining the original 2:1 ratio of PsA-TT:PsACWY recipients (60 and 30 subjects, respectively, in each age group). Available sera obtained from these subjects at study weeks 0, 4, and 52 were tested in hSBA assays blinded to vaccine group. The rSBA and anti-PsA IgG concentrations for the subset tested for hSBA were compared to those of the whole study population and indicated that the subset was similar to the study population (data not shown).
PsA-TT Immunogenicity by hSBA Assay
The hSBA GMTs at weeks 0, 4, and 52 are shown in Figure 1A -C. The proportions of subjects with hSBA titers ≥8 and with ≥4-fold rise are shown in Tables 1-3 . Comparing vaccine groups, the hSBA responses to PsA-TT were significantly higher than those to PsACWY for the combined age groups, and for each age group in terms of hSBA GMTs ( Figure 1B ) and percentage with ≥4-fold rise in hSBA titers (Table 2 ) at study week Figure 1 . Human complement serum bactericidal activity (hSBA) and rabbit complement serum bactericidal activity (rSBA) geometric mean titers (GMTs), and group A polysaccharide (PsA)-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs), for preimmunization (week 0) (A), 4 weeks postimmunization (B), and 52 weeks postimmunization (C). *P ≤ .05, **P ≤ .001, ***P ≤ .0001 between vaccine groups. Error bars are 95% CI.
4. The proportions with hSBA titers ≥8 at week 4 were only significantly different between PsA-TT and PsACWY groups in the age groups 2-5 and 6-10 years ( Table 2 ). The effect of age on vaccine response differed between the 2 vaccines. The PsA-TT vaccine elicited hSBA responses at week 4 that were not significantly lower in subjects aged 2-5 and 6-10 years compared with subjects aged 11-17 and 18-29 years ( Figure 1B , Table 4 ). However, in the PsACWY-immunized groups, hSBA titers were significantly lower in the age groups 2-5 and 6-10 years compared with the titers measured in PsACWYimmunized subjects aged 11-17 and 18-29 years ( Figure 1B , Table 4 ). At week 52, the hSBA titers were decreased compared with week 4 levels in all age groups, regardless of vaccine. However, the hSBA GMTs and proportion with hSBA titers ≥8 in the PsA-TT vaccine group remained significantly higher than the PsACWY group for the age groups 2-5 and 6-10 years (Figure 1C and Table 3 ).
Comparison of Immunogenicity Analyses Using Serum Anti-PsA IgG Concentrations Versus SBA Titers
Prior to immunization, both the PsA-TT and PsACWY groups had preexisting PsA-specific IgG antibodies. Children 2-5 years of age had the lowest preimmunization anti-PsA IgG levels, which increased with age ( Figure 1A ). This was not unexpected, as anti-PsA antibody concentrations have been shown to increase with age in Burkina Faso [21] . The hSBA, but not rSBA, showed a similar relationship between age and baseline titers. One month following immunization, both the PsA-TT and PsACWY vaccine groups had increased anti-PsA IgG concentrations compared to baseline. As with both SBAs, the antiPsA IgG results indicated the PsA-TT vaccine was significantly more immunogenic compared with the PsACWY vaccine in all age groups. Consistent with hSBA but not rSBA, anti-PsA IgG responses to PsACWY were lower in those aged 2-5 and 6-10 years compared with responses in subjects aged 11-17 and 18-29 years ( Figure 1B , Table 4 ). By study week 52, anti-PsA IgG concentrations were considerably lower compared with those present at week 4, and the decrease was greatest in the younger age groups following vaccination with either PsA-TT or PsAC-WY. This pattern of decline was also observed for hSBA but not rSBA titers ( Figure 1C ). The proportion of PsA-TT-vaccinated individuals with anti-PsA IgG concentrations at or above the threshold remained high for all age groups, whereas the proportion with hSBA titers ≥8 was low in young children, consistent with a qualitative difference in antipolysaccharide antibodies measured by the 2 assays (Table 3) .
Comparisons of Immunogenicity Analyses Using hSBA Versus rSBA Assays
Prior to immunization, a significantly greater number of individuals had rSBA titers ≥128 compared to those with hSBA titers ≥8 (72.1% and 82.9% vs 34.7% and 39.5% for each vaccine group, respectively). At 4 weeks following immunization, both rSBA and hSBA GMTs and the proportions with titers at or above thresholds increased compared to preimmunization levels in both the PsA-TT and PsACWY vaccine groups, and the immune responses to PsA-TT were higher than those to the PsACWY vaccine. However, the rSBA and hSBA results differed with respect to the response to PsACWY vaccine. Unlike the age-dependent responses to PsACWY shown by the hSBA assay (and anti-PsA IgG ELISA), the rSBA assay analyses showed similar responses across all age groups (Table 4 ). This highlights a striking difference between the SBA assays in characterizing responses to PsACWY. The lack of discrimination between age groups both prior to immunization and in response to PsACWY vaccine raises questions about the relationship between SBA thresholds and protection, particularly in young children. By week 52, differences between the hSBA and rSBA titers were more pronounced than at earlier time points. Regardless of the vaccine or age group, fewer subjects maintained a ≥4-fold rise from baseline in hSBA titer than in rSBA titer. Furthermore, the proportions at or above threshold titers were much lower for hSBA than for rSBA (Table 3) . Using a higher threshold of 2048, rSBA showed differences in antibody persistence between the 2 vaccines for all age groups, but age group differences in the proportions at or above this threshold for the PsACWY vaccine were not significant (Table 3) . This is inconsistent with the observation that protection following PsACWY declines more rapidly in young children [22, 23] . Alternatively, at week 52 only 50% of young adults who received PsACWY had an hSBA titer ≥8 in contrast to historical evidence that PsA vaccine efficacy extends beyond 1 year. The comparison between proportions above hSBA and rSBA threshold titers at week 52 suggests the potential for underestimation and overestimation of protection, respectively.
Assay Correlation and Agreement
The immunoassays were also compared using the results for individual serum samples in correlation and agreement analyses. These were conducted using all available results, and separately by vaccine groups, by time points, by age groups, and by all these factors combined. No meaningful correlation was observed; the coefficients of correlation between each of the 3 assays overall were <0.60. The highest correlation using a Spearman correlation coefficient was 0.76 for hSBA and IgG at week 4 in the PsA-TT group aged 2-5 years. Similarly, agreement for 4-fold rise or for threshold results between assays was poor. We used the κ statistic to explore the agreement within and between assays using rSBA thresholds of 8, 128, and 2048, hSBA thresholds of 4 and 8, and IgG thresholds of 0.15 µg/mL and 2 µg/mL, overall and at each time point. The κ statistic was quite low (κ < 0.6) for almost all of the comparisons. Notable exceptions were κ ≥ 0.95 when comparing rSBA ≥ 8 to rSBA ≥ 128 overall and at weeks 0, 4, and 52. κ was also ≥0.80 when comparing hSBA ≥ 4 to hSBA ≥ 8 at week 4.
DISCUSSION
Since introduction of the PsA-TT vaccine in Burkina Faso in 2010, the incidence of MenA meningitis and carriage has decreased dramatically in vaccinated populations [5, 24] . This study is a continuation of a previously published study that demonstrated higher bactericidal rSBA antibody and anti-PsA antibody responses 4 weeks following 1 vaccination with PsA-TT compared with PsACYW in 2-to 29-year-olds [17] . We have extended the original analysis to include hSBA titers at 4 and 52 weeks following immunization. Overall, the hSBA data indicate that the PsA-TT vaccine was more immunogenic than the PsACWY vaccine, eliciting significantly higher hSBA titers 4 weeks postimmunization in the combined age groups. More importantly, following PsA-TT immunization, hSBA titers were similar between the 2-5 and 6-10-year age groups and the 11-17 and 18-29-year age groups at 4 weeks postimmunization. This is an important characteristic of PsA-TT, as 2-to 10-year-olds have been demonstrated to be more at risk for MenA disease than adolescents or adults during nonepidemic periods in sub-Saharan Africa [25] . These observations were consistent with the immune responses as evaluated by rSBA assays and anti-PsA IgG ELISAs [17] . Differences among the results generated by each of the assays were also observed. Prior to immunization, the presence of naturally acquired antibodies increased with age by hSBA assay and by IgG ELISA, whereas titers were relatively high for all age groups by rSBA assay. Similarly, age-group-distinct responses to the PsACWY vaccine were apparent by hSBA assay and IgG ELISA only. PsA vaccines have been successfully used for outbreaks and control of epidemics, but the persistence of protection in young children following PsA vaccination is not well documented. The distinction between age groups was greatest with hSBA assays; lower responses to PsACWY were observed for those aged 2-5 and 6-10 years. By IgG ELISA, the response to PsACWY in 6-to 10-year-olds was higher than in 2-to 5-year-olds, but both were significantly lower than in adolescents and adults.
By week 52, hSBA and rSBA results were divergent, especially in the age groups 2-5 and 6-10 years. The decline in hSBA following PsA-TT in young children is inconsistent with the results shown by rSBA that indicate sustained high titers regardless of the age group or the vaccine used. These results are not without precedent, as previous studies using conjugated polysaccharide vaccines demonstrated marked reduction in hSBA titers against MenA at 1 year compared with titers measured at 1 month following vaccination [26] . In contrast, rSBA titers have been demonstrated to remain high 1 year postimmunization and as far as 3 years postimmunization [27, 28] .
Neisseria meningitidis is more sensitive to bactericidal killing in rabbit complement compared with human complement [29] . The ability of N. meningitidis to bind human but not rabbit factor H has been used, in part, to explain the disparity between the 2 sources of complement and bactericidal activity [13] . Anti-Ps immunoglobulin M has also been shown to be more effective at killing N. meningitidis in rabbit vs human complement [15] . For MenA, the differences in bactericidal killing using either human or rabbit complement is further complicated by the fact that little correlation between the 2 assays has been demonstrated here and elsewhere [14, 30] .
In clinical trials conducted in Finland during the 1970s using PsA vaccines, efficacy was related to immunogenicity measured by the amount of anti-PsA antibodies in the sera. An anti-PsA antibody concentration ≥2 µg/mL was considered protective, as this was the mean anti-PsA Ig level measured in adults, a population resistant to MenA disease [2, 31] . However, this is a population-based estimate, and no clear immunologic marker of protection in the African meningitis belt has been described. For example, in Burkina Faso prior to the PsA-TT vaccine introduction, the highest incidence of MenA disease was among those aged 15-19 years, an age group that had anti-PsA IgG levels well above the 2 µg/mL threshold [21] . In addition, high incidence rates in young adults up to 29 years of age have also been documented in other MenA epidemics despite the prevalence of high anti-PsA IgG concentrations among this age group in the meningitis belt [32] [33] [34] . Similarly, as demonstrated here and elsewhere, a high percentage of adolescents and young adults have rSBA titers ≥128 prior to immunization, even though this age group is vulnerable to MenA disease during epidemics [21, 32] . Discrepancies clearly exist between serologic markers of protection, the different assays used to measure them, and patterns of clinical disease within the meningitis belt.
The ability to sustain MenA carriage within a population may be the most essential factor for disease. With high rates of carriage, invasive disease may occur even when the susceptible population is small. Following PsA-TT vaccination on a public health scale in Burkina Faso, carriage of MenA has been almost eliminated [35] . The effect of vaccination on carriage is difficult to associate with a serologic marker using the data generated in the MenAfriVac campaign, as the response to PsA-TT was high by all assays used to measure it. Although differences among the assay results were observed at 1 year following immunization, a correlate could not be identified, as no MenA carriage was detected in the vaccinated population.
Regardless of the discrepancies between hSBA and rSBA titers and anti-PsA IgG as presented here, the PsA-TT vaccine has had a dramatic effect in the field. To date, no individuals immunized with PsA-TT have become ill due to MenA [5] . The effect on carriage represents a major improvement over the PsA vaccines, which lack the ability to block carriage [24, 36] . MenA disease has also been eliminated in countries that have reached partial vaccination status, demonstrating effective herd protection. MenA, however, is still active in the meningitis belt, as has been recently demonstrated in the unvaccinated country of Guinea [5] .
The success of the PsA-TT vaccine and public-health-scale immunization campaigns is a long-awaited achievement. Maintaining immunity in the population is a long-term goal, but specific serologic markers of protection remain unclear, making continued surveillance in the meningitis belt a necessary priority. Continued surveillance combined with studies of anti-PsA antibody and both rSBA and hSBA persistence, especially in vulnerable populations such as infants and children, are warranted to guide optimal immunization programs for expanding and maintaining MenA-free sub-Saharan African regions.
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